Ousheng Technology Completes Pre-B Financing Round to Accelerate the Development of a Continuous Flow Chemistry Intelligent Manufacturing Platform

Recently, Oushisheng (Beijing) Technology Co., Ltd., a leading domestic enterprise in the research, development, and manufacturing of continuous flow systems, announced the completion of its pre-B financing round amounting to tens of millions of RMB. This round was led by Dalton Venture, with existing shareholder Long Hill Capital continuing to increase its investment. Following this financing, Oushisheng will further enrich its product portfolio, accelerate the expansion of its commercialization network, and enter overseas markets, thereby solidifying its industry-leading position.

Oushisheng is a provider of complete solutions for flow chemistry, with multidisciplinary R&D and application research teams. Currently, the FLOW R&D Laboratory of its Application Research Department has established in-depth collaborations with multiple research teams, including those at Tsinghua University, enabling it to deliver robust technical support to users across various industries.

• Establishing a Complete Flow Chemistry Lab

• Providing Automated and Intelligent Multi-Step Synthesis Solutions

• Custom Development of High-End Core Components

• Process Route Development, Process Scale-up, and Equipment Development

• Precision Manufacturing of Continuous Flow Microreactor Equipment

In addition to its industry-leading flow chemistry reaction systems, Oushisheng also provides clients with a multi-module suite of services, including scientific equipment design, R&D outsourcing, process optimization, scale-up studies, equipment and process research, precision manufacturing, and continuous flow process training. Focusing on process scalability, Oushisheng specializes in translating research outcomes from laboratory scale to pilot plant scale, and has successfully launched versatile continuous automated synthesis systems and embedded modular systems.

With its innovative products and comprehensive application services, Oushisheng has established business collaborations with hundreds of leading enterprises across various niche sectors both domestically and internationally, spanning industries such as pharmaceuticals, chemicals, catalysts, new energy, semiconductors, and scientific research. Its business demonstrates strong scalability and resilience to economic cycles.

As a new generation of foundational production paradigms,Continuous Production Technology via Flow Chemistry Offers Multifaceted Advantages, Enabling Comprehensive Enhancements in Safety, Efficiency, Cost-Effectiveness, and Sustainability Across the Entire R&D and Manufacturing System：

According to public information, continuous manufacturing technologyCost savings average 10%–50%, and production cycles are shortened by more than half., with substantial reductions in waste emissions and carbon footprint. Given the significant benefits, multinational pharmaceutical companies such as Pfizer, GSK, Novartis, and Eli Lilly have actively invested in this area, and the FDA has already approved more than 10 new drug applications utilizing continuous manufacturing processes. Leading domestic CXO companies, including WuXi AppTec, Porton Pharma, and Asymchem, have also identified continuous flow technology platforms as a key direction for their future development.

In recent years, policy-level initiatives have continuously raised new requirements for the industrial upgrading of manufacturing, aligning with the overarching theme of developing "new quality productive forces" that are safer, smarter, and greener. In February this year, the Ministry of Industry and Information Technology and six other departments jointly issued the Guiding Opinions on Accelerating the Green Development of Manufacturing. In the same month, the Work Safety Committee of the State Council also released the Three-Year Action Plan for Fundamental Improvement and Critical Breakthroughs in Work Safety (2024–2026). Both documents will significantly promote the industrial application of continuous flow technology at both macro and micro levels.

Jin Yingze, founder of Oushisheng, stated, “While policy support is certainly a significant driver of technological development, the demands of industry players are the primary force behind the widespread adoption of technology. In the post-pandemic era, clients across various sectors are facing growth challenges and operational difficulties.”Our products effectively address customers' pain points, helping them increase revenue, reduce costs, and improve efficiency., it is precisely because we have created indispensable value for our clients that in 2023Our own performance also achieved growth of over 50%.”

Regarding this financing round, Jin Yingze stated: The company secured financing amidst an extremely challenging market environment. We first extend our gratitude to Dalton Venture for its recognition and to Long Hill Capital, our existing shareholder, for its continued support. This further strengthens our resolve to become a leader in the industrial application of continuous flow technology. Moving forward, leveraging our accumulated technological expertise and advantages in interdisciplinary integration, we will achieve breakthroughs in chemical synthesis, catalyst development equipment, and key components for industrial intelligence. We will continue to deepen our presence in both the scientific research and industrial markets while accelerating our global expansion.

Sun Qi, Founding Managing Partner of Dalton Venture, stated: Against the backdrop of urgent industrial upgrading and “trade-in” initiatives in the pharmaceutical, fine chemical, and scientific instrumentation sectors, the high safety, high reaction efficiency, and low cost of continuous flow technology have become an industry consensus and are widely adopted. As one of the few leading companies offering comprehensive solutions, Oushisheng looks forward to creating greater value for more downstream customers.

Jiang Xiaodong, Partner at Long Hill Capital, stated: Since Long Hill Capital invested in Oushisheng, we have witnessed the company’s significant progress in product development and commercialization. Amid the current industry downturn, the company has demonstrated strong resilience and counter-cyclical capabilities, achieving sustained revenue growth against the headwinds and successfully expanding into overseas markets. Leveraging its foundational technological capabilities and proprietary products, the company has established benchmark clients in many emerging industries, including semiconductors, fully demonstrating the high scalability of its products and business. As the lead institutional investor in Oushisheng’s first financing round, Long Hill Capital will continue to support the company’s development as always.

Dalton Venture focuses on forward-looking medical innovation technologies and serves as the early-stage exclusive investor for multiple first-of-their-kind technology projects in China. Its investment portfolio encompasses VC funds, as well as angel funds in the Yangtze River Delta and the Greater Bay Area. The core team hails from the healthcare industry, with a track record of successfully incubating early-stage startups and founding and managing public companies with market capitalizations exceeding RMB 10 billion. Adhering to the philosophy of being not only a value discoverer but also a value creator, Dalton Venture has received numerous accolades, including rankings among the Top 100 VCs and Top 20 Medical Device Investors by Zero2IPO. Notable portfolio companies include Landin Medicine, Deepwise Healthcare, Hannuo Medical, Triastek, and Heyuan Biology.

Long Hill Capital is a new generation of theme-driven venture capital funds. In the fields of big health and aging, Long Hill Capital is committed to investing in technology-driven business model innovations, making longevity a gift of life for everyone in China’s rapidly aging society. Long Hill Capital has offices in Shanghai and Beijing, with total assets under management reaching RMB 6 billion. Its investors include top-tier institutional investors such as endowment funds from globally renowned universities and hospitals, foundations, pension funds, and leading funds of funds. Long Hill Capital is dedicated to continuously creating value for the growth and development of companies in emerging sectors.